Subcellular localization of Mdm2 expression and prognosis of breast cancer

International Journal of Clinical Oncology

Volumn 19, Issue 5, 2014, Pages 842-851

  Park, Hyung Seok ^a   Park, Ji Min ^a   Park, Seho ^a   Cho, Junghoon ^a   Kim, Seung Il ^a   Park, Byeong Woo ^a  

^a Yonsei University College of Medicine   (South Korea)

Author keywords

Breast; Neoplasms; p53; Prognosis; Proto oncogene proteins c mdm2

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; KI 67 ANTIGEN; PROTEIN MDM2; PROTEIN P53; MDM2 PROTEIN, HUMAN; TP53 PROTEIN, HUMAN; TUMOR MARKER;

ADULT; ARTICLE; CANCER PROGNOSIS; CANCER SIZE; CANCER SURGERY; CANCER SURVIVAL; CELLULAR DISTRIBUTION; CONTROLLED STUDY; CYTOPLASM; DISEASE FREE SURVIVAL; EVALUATION STUDY; FEMALE; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVERALL SURVIVAL; PROTEIN EXPRESSION; TISSUE MICROARRAY; TRIPLE NEGATIVE BREAST CANCER; ANIMAL; BIOSYNTHESIS; BREAST TUMOR; GENE EXPRESSION REGULATION; GENETICS; METABOLISM; MIDDLE AGED; MOUSE; NUCLEOLUS; PATHOLOGY; PROGNOSIS;

ADULT; ANIMALS; BREAST NEOPLASMS; CELL NUCLEOLUS; CYTOPLASM; DISEASE-FREE SURVIVAL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MICE; MIDDLE AGED; PROGNOSIS; PROTO-ONCOGENE PROTEINS C-MDM2; RECEPTOR, ERBB-2; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; TUMOR SUPPRESSOR PROTEIN P53;

EID: 84919343110     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-013-0639-1     Document Type: Article

References (37)

1. Toledo F, Wahl GM (2006) Regulating the p53 pathway: in vitro hypotheses, in vivo veritas. Nat Rev Cancer 6:909–923
2. Vousden KH, Prives C (2009) Blinded by the light: The growing complexity of p53. Cell 137:413–431
3. O’Connor PM, Jackman J, Bae I et al (1997) Characterization of the p53 tumor suppressor pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57:4285–4300
4. Scata KA, El-Deiry WS (2007) p53, BRCA1 and breast cancer chemoresistance. Adv Exp Med Biol 608:70–86
5. Fang S, Jensen JP, Ludwig RL et al (2000) Mdm2 is a RING finger-dependent ubiquitin protein ligase for itself and p53. J Biol Chem 275:8945–8951
6. Oliner JD, Kinzler KW, Meltzer PS et al (1992) Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 358:80–83
7. Haupt Y, Maya R, Kazaz A et al (1997) Mdm2 promotes the rapid degradation of p53. Nature 387:296–299
8. Kubbutat MH, Jones SN, Vousden KH (1997) Regulation of p53 stability by Mdm2. Nature 387:299–303
9. Fakharzadeh SS, Trusko SP, George DL (1991) Tumorigenic potential associated with enhanced expression of a gene that is amplified in a mouse tumor cell line. EMBO J 10:1565–1569
10. Steinman HA, Burstein E, Lengner C et al (2004) An alternative splice form of Mdm2 induces p53-independent cell growth and tumorigenesis. J Biol Chem 279:4877–4886
11. Brekman A, Singh KE, Polotskaia A et al (2011) A p53-independent role of Mdm2 in estrogen-mediated activation of breast cancer cell proliferation. Breast Cancer Res 13:R3
12. Sanchez M, Picard N, Sauve K et al (2013) Coordinate regulation of estrogen receptor beta degradation by Mdm2 and CREB-binding protein in response to growth signals. Oncogene 32:117–126
13. Kim K, Burghardt R, Barhoumi R et al (2011) MDM2 regulates estrogen receptor alpha and estrogen responsiveness in breast cancer cells. J Mol Endocrinol 46:67–79
14. Marchetti A, Buttitta F, Girlando S et al (1995) mdm2 gene alterations and mdm2 protein expression in breast carcinomas. J Pathol 175:31–38
15. Karray-Chouayekh S, Baccouche S, Khabir A et al (2011) Prognostic significance of p16INK4a/p53 in Tunisian patients with breast carcinoma. Acta Histochem 113:508–513
16. Abdel-Fatah TM, Powe DG, Agboola J et al (2010) The biological, clinical and prognostic implications of p53 transcriptional pathways in breast cancers. J Pathol 220:419–434
17. Bueso-Ramos CE, Manshouri T, Haidar MA et al (1996) Abnormal expression of MDM-2 in breast carcinomas. Breast Cancer Res Treat 37:179–188
18. Hori M, Shimazaki J, Inagawa S et al (2002) Overexpression of MDM2 oncoprotein correlates with possession of estrogen receptor alpha and lack of MDM2 mRNA splice variants in human breast cancer. Breast Cancer Res Treat 71:77–83
19. Vestey SB, Sen C, Calder CJ et al (2004) p14ARF expression in invasive breast cancers and ductal carcinoma in situ–relationships to p53 and Hdm2. Breast Cancer Res 6:R571–R585
20. Hori M, Shimazaki J, Inagawa S et al (2000) Alternatively spliced MDM2 transcripts in human breast cancer in relation to tumor necrosis and lymph node involvement. Pathol Int 50:786–792
21. Lukas J, Gao DQ, Keshmeshian M et al (2001) Alternative and aberrant messenger RNA splicing of the mdm2 oncogene in invasive breast cancer. Cancer Res 61:3212–3219
22. Bartel F, Taubert H, Harris LC (2002) Alternative and aberrant splicing of MDM2 mRNA in human cancer. Cancer Cell 2:9–15
23. Baunoch D, Watkins L, Tewari A et al (1996) MDM2 overexpression in benign and malignant lesions of the human breast. Int J Oncol 8:895–899
24. Choschzick M, Heilenkotter U, Lebeau A et al (2010) MDM2 amplification is an independent prognostic feature of node-negative, estrogen receptor-positive early-stage breast cancer. Cancer Biomark 8:53–60
25. Elston CW, Ellis IO (1991) Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology 19:403–410
26. Goldhirsch A, Wood WC, Coates AS et al (2011) Strategies for subtypes—dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol 22:1736–1747
27. Park S, Park HS, Koo JS et al (2012) Breast cancers presenting luminal B subtype features show higher discordant human epidermal growth factor receptor 2 results between immunohistochemistry and fluorescence in situ hybridization. Cancer 118:914–923
28. Hammond ME, Hayes DF, Dowsett M et al (2010) American Society of Clinical Oncology/College Of American Pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28:2784–2795
29. Carter S, Bischof O, Dejean A et al (2007) C-terminal modifications regulate MDM2 dissociation and nuclear export of p53. Nat Cell Biol 9:428–435
30. Al-Kuraya K, Schraml P, Torhorst J et al (2004) Prognostic relevance of gene amplifications and coamplifications in breast cancer. Cancer Res 64:8534–8540
31. Galmarini CM, Clarke ML, Falette N et al (2002) Expression of a non-functional p53 affects the sensitivity of cancer cells to gemcitabine. Int J Cancer 97:439–445
32. Nishida T, Yamada Y (2011) The nucleolar SUMO-specific protease SMT3IP1/SENP3 attenuates Mdm2-mediated p53 ubiquitination and degradation. Biochem Biophys Res Commun 406:285–291
33. O’Keefe K, Li H, Zhang Y (2003) Nucleocytoplasmic shuttling of p53 is essential for MDM2-mediated cytoplasmic degradation but not ubiquitination. Mol Cell Biol 23:6396–6405
34. Muller S, Hoege C, Pyrowolakis G et al (2001) SUMO, ubiquitin’s mysterious cousin. Nat Rev Mol Cell Biol 2:202–210
35. Melchior F, Hengst L (2000) Mdm2-SUMO1: is bigger better? Nat Cell Biol 2:E161–E163
36. Wang H, Ma X, Ren S et al (2011) A small-molecule inhibitor of MDMX activates p53 and induces apoptosis. Mol Cancer Ther 10:69–79
37. Maeda T, Hobbs RM, Merghoub T et al (2005) Role of the proto-oncogene Pokemon in cellular transformation and ARF repression. Nature 433:278–285